We have observed
6 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER
ENHANCEMENT OF PLACENTAL STEM CELL POTENCY USING MODULATORY RNA MOLECULES
IMPROVED REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS